Study evaluates use of extended-release niacin

03/28/2012 |

About 3.5% of patients with hyperlipidemia who used a combination of extended-release niacin and ezetimibe/simvastatin met the criteria for new onset diabetes at 64 weeks, compared with 2.6% in those taking E/S alone, according to a study in Diabetes Care. The researchers said those taking niacin had increased fasting glucose levels, but the cases went away without intervention.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health